Skip to main
RCEL

RCEL Stock Forecast & Price Target

RCEL Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AVITA Medical is positioned for strong future growth with its innovative RECELL system, which has received approval in the US and international markets. The recent Cohealyx clinical data and portfolio expansion highlight the company's strategy of offering a comprehensive wound care platform aimed at improving healing outcomes. With a strong clinical foundation and management signaling a return to execution-led growth, AVITA Medical is expected to continue to see revenue growth and operational improvement in the future.

Bears say

AVITA Medical is grappling with several challenges, including significant reliance on a single product and a focus on the US market. Despite gaining product approval in multiple international markets, the company has not actively marketed in those territories, hindering potential revenue growth. Additionally, competition from other wound care solutions, regulatory and financial risks, and potential legal and intellectual property disputes may pose further challenges for the company.

RCEL has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AVITA Medical Inc (RCEL) Forecast

Analysts have given RCEL a Strong Buy based on their latest research and market trends.

According to 3 analysts, RCEL has a Strong Buy consensus rating as of Jun 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AVITA Medical Inc (RCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.